|
Mar 14
|
Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer
|
|
Mar 13
|
Amgen’s gMG therapy cuts disease symptoms at one-year mark
|
|
Mar 13
|
Amgen (NasdaqGS:AMGN) Announces Promising MINT Trial Data For UPLIZNA In Generalized Myasthenia Gravis
|
|
Mar 13
|
Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy According to Hedge Funds?
|
|
Mar 13
|
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
|
|
Mar 13
|
Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?
|
|
Mar 13
|
Amgen Says Phase 3 Data Support Uplizna's Efficacy in Generalized Myasthenia Gravis
|
|
Mar 13
|
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
|
|
Mar 12
|
Amgen Inc. (AMGN): Among Dobermans of the Dow to Buy
|
|
Mar 11
|
HALO vs. AMGN: Which Stock Is the Better Value Option?
|
|
Mar 10
|
Stock market sell-off: Why these stocks are in the green amid the pain
|
|
Mar 10
|
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
|
|
Mar 10
|
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints
|
|
Mar 10
|
Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus
|
|
Mar 4
|
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
|
|
Mar 3
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Mar 3
|
Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP
|
|
Mar 1
|
POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
|
|
Feb 28
|
Amgen Inc. (AMGN) Invests $200M in AI-Focused Tech Center in India, Plans to Hire 2,000 by 2025
|
|
Feb 28
|
AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
|